EGFR and Abnormal blood ion concentration: Thus, in order to better understand the overall risk of electrolyte disorders, we conducted a meta-analysis of published randomized controlled trials (RCTs) to investigate the incidence and RR of all-grade and grade 3/4 electrolyte disorders during the treatment of anti-EGFR MoAbs (cetuximab or panitumumab).